Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates

Core Insights - Taysha Gene Therapies, Inc. reported a quarterly loss of $0.07 per share, which was better than the Zacks Consensus Estimate of a loss of$0.08, representing an earnings surprise of 12.50% [1] - The company generated revenues of $2.02 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 6.42$3.6 million in the same quarter last year [2] - The stock has underperformed the market, losing about 1.7% since the beginning of the year compared to the S&P 500's gain of 1.3% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of$2.63 million, and for the current fiscal year, it is -$0.37 on revenues of$9.73 million [7] - The estimate revisions trend for Taysha Gene Therapies is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Generic Drugs industry, to which Taysha Gene Therapies belongs, is currently ranked in the bottom 24% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Taysha's stock performance [5]